Allergy Shots Long-Term Side Effects: A Year-by-Year Patient Guide

No — decades of surveillance data find no evidence that completing a full course of allergy shots causes long-term immune system damage. The AAAAI/ACAAI National Surveillance Study covering 54 million injection visits and independent registry studies have found no cumulative immune dysfunction attributable to SCIT. In fact, the opposite appears to be true: a 2012 Danish nationwide registry study by Linneberg (JACI) found SCIT-treated patients had lower autoimmune disease risk and lower all-cause mortality compared to patients managed with conventional allergy medications. SCIT induces immune tolerance — a regulatory change — not immune suppression.

Fatigue from allergy shots generally improves over time, not worsens. Post-injection fatigue is most pronounced during the build-up phase, particularly in weeks 4-12 when dose escalation is most aggressive and the immune system is most actively responding to each injection. The mechanism involves pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha) triggering hypothalamic sickness-behavior signaling — the same mechanism as post-vaccination fatigue. As SCIT shifts the immune response toward Treg/IgG4 dominance over months, the magnitude of cytokine release per injection typically decreases, and most patients report that maintenance-phase injections produce little or no notable fatigue. Fatigue worsening instead of improving warrants evaluation for unrelated conditions like thyroid dysfunction or anemia.

Stopping allergy shots before completing the recommended 3-5 year course means trading away much of the durability that makes SCIT worth the multi-year commitment. Eng et al. (Allergy 2006) found that 10-25% of patients experience symptom return within 3 years of stopping, with higher relapse rates correlated with shorter treatment duration. Durham et al. (NEJM 1999) documented that the 7-12 year post-treatment benefit window applies to patients who completed a full course — not those who stopped early. If you stop during build-up, you lose the maintenance-phase dose exposure that drives long-term tolerance. Retreatment after relapse is effective, but involves restarting the build-up process. Discuss timing with your allergist before deciding to stop.

Aluminum in allergy shots is not a meaningful long-term safety concern for most patients in the United States. US allergist practices predominantly use aqueous and glycerinated extracts — not aluminum-adsorbed depot formulations — so most American SCIT patients receive essentially zero aluminum adjuvant in their injections. For the minority of patients receiving aluminum-adsorbed extracts (more common in European practice), cumulative aluminum exposure over a 3-5 year course runs approximately 10-50 mg, comparable to normal dietary aluminum intake over the same period (Flarend et al., Vaccine 1997). No systemic aluminum toxicity has been documented in SCIT surveillance data. The documented aluminum-related complication — subcutaneous nodules — is a localized injection-site issue, not a systemic toxicity.

There is no credible evidence from controlled studies that allergy shots cause autoimmune disease. Theoretical concerns from individual case reports have not been reproduced at the population level. The Linneberg 2012 Danish nationwide registry study — one of the strongest available datasets — found SCIT-treated patients had significantly lower autoimmune disease risk compared to matched controls (HR 0.76). Eifan and Durham's 2012 comprehensive safety review reached the same conclusion: no autoimmune disease signal attributable to SCIT has emerged in decades of clinical surveillance. Active autoimmune disease is listed as a relative or absolute contraindication for SCIT in current guidelines — precautionary rather than evidence-based — because initiating any immune-modifying treatment during active autoimmune flare is clinically cautious.

Clinical benefits from a completed allergy shot course typically persist for 7-12 years after discontinuation. Durham et al. (NEJM 1999) demonstrated sustained benefit at 3 years after stopping in grass-pollen SCIT patients who completed a full 3-5 year course. Jacobsen et al. (Allergy 2007) in the PAT study found protection against asthma development lasting 10 years after stopping. The durability depends on completing the full course — partial treatment courses provide less durable benefits. A 10-25% relapse rate within 3 years of stopping (Eng et al., Allergy 2006) means most patients retain benefit long-term, but a meaningful minority does need retreatment. Retreatment after documented relapse is considered effective and is supported by practice guidelines.